SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

BRIEF-Genentech To Present Data From Phase III Study Of Cancer Immunotherapy In Early, Resected Lung Cancer

05/11/2021 01:10
BRIEF-Genentech To Present Data From Phase III Study Of Cancer Immunotherapy In Early, Resected Lung Cancer

- Roche Holding AG ROG.S:

  • GENENTECH TO PRESENT DATA FROM ONE OF MOST COMPREHENSIVE ONCOLOGY PORTFOLIOS AT 2021 ASCO ANNUAL MEETING SHOWCASING ADVANCEMENTS FOR PEOPLE LIVING WITH CANCER

  • DATA FROM FIRST POSITIVE PHASE III STUDY OF A CANCER IMMUNOTHERAPY IN EARLY, RESECTED LUNG CANCER

  • - STUDIES IN PERSONALIZED HEALTHCARE EXPLORING TUMOR AGNOSTIC TREATMENTS THAT DEMONSTRATE IMPACT OF COUPLING BIOMARKER TESTING WITH TARGETED THERAPIES TO DEVELOP INDIVIDUALIZED TREATMENT PLANS -

  • - NEW DATA, AND DRUG COMBINATION STRATEGIES FOR TREATMENT OF LYMPHOMA FROM LARGEST HEMATOLOGY PORTFOLIO IN INDUSTRY -

Source text for Eikon: ID:nBw4swcSLa

Further company coverage: ROG.S


(Berlin Speed Desk)

(([email protected];))